Neurologic diseases in HIV-infected patients

Handbook of Clinical Neurology

Volumn 121, Issue , 2014, Pages 1321-1344

  Bilgrami, Mohammed ^a   O'keefe, Paul ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CMV encephalitis; Cryptococcal meningitis; Highly active antiretroviral therapy (HAART); HIV associated neurocognitive disorder (HAND); Neurosyphilis; Primary central nervous system lymphoma (PCNSL); Progressive multifocal leukoencephalopathy (PML); Toxoplasma encephalitis; Vacuolar myelopathy (VM)

Indexed keywords

EID: 84898702865     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-7020-4088-7.00090-0     Document Type: Chapter

References (103)

1. Albright A., Soldan S., Gonzalez-Scarano F., et al. Pathogenesis of human immunodeficiency virus induced neurological disease. J. Neurovirol. 2003, 9:222-227.
2. Antinori A., Ammassari A., De Luca A., et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 1997, 48:687-694.
3. Alport A., Sander H. Clinical approach to peripheral neuropathy. Anatomic localization and diagnostic testing. Continuum Lifelong Learning Neurol 2012, 18:13-38.
4. Antinori A., Arendt G., Becker J.T., et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
5. Batungwanayo J., Taelman H., Bogaerts J., et al. Pulmonary cryptococcosis associated with HIV-1 infection in Rwanda: a retrospective study of 37 cases. AIDS 1994, 8:1271-1276.
6. Berger J., Brew B. An international screening tool for HIV dementia. AIDS 2005, 19:2165-2166.
7. Berenguer J., Moreno S., Laguna F., et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 1992, 326:668.
8. Bhaskaran K., Mussini C., Antinori A., et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann. Neurol. 2008, 63:213-221.
9. Bicanic T., Meintjes G., Wood R., et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin. Infect. Dis. 2007, 45:76-80.
10. Blumberg H., Burman W., Chaisson R., et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 2003, 167:603-662.
11. Boulware D., Meya D., Bergemann T., et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010, 7:e1000384.
12. Brack-Werner R. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS 1999, 131:1-22.
13. Brew B. AIDS dementia complex. HIV Neurology, Contemporary Neurology Series 2001, Vol. 61:62-81. Oxford University Press, New York.
14. Brouwer A., Rajanuwong A., Chierakul W., et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial. Lancet 2004, 363:1764-1767.
15. Buchacz K., Baker R., Palella F., et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007. AIDS 2010, 24:1549-1559.
16. Burman W., Gallicano K., Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin. Infect. Dis. 1999, 28:419-429.
17. Cecchini D., Ambrosioni J., Brezzo C., et al. Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. AIDS 2007, 21:373-374.
18. Cinque P., Vago L., Ceresa D., et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 1998, 12:389-394.
19. Cinque P., Pierotti C., Vigano M.G., et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J. Neurovirol. 2001, 7:358-363.
20. Clifford D. IAS-USA. Improving the Management of HIV Disease 2012, Chicago, IL. http://www.iasusa.org/cme/2012-s/chicago/syllabus.
21. Collis T., Celum C. The clinical manifestations and treatment of sexually transmitted diseases in human immunodeficiency virus-positive men. Clin. Infect. Dis. 2001, 32:611-622.
22. Cornblath D., McArthur J., Kennedy P., et al. Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann. Neurol. 1987, 21:32-40.
23. Dal Pan G., Glass J., McArthur J., et al. Clinicopathologic correlations of HIV associated vacuolar myelopathy. Neurology 1994, 44:2159.
24. Darras-Joly C., Chevret S., Wolff M., et al. Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Clin. Infect. Dis. 1996, 23:369-376.
25. Di Rocco A., Werner P., Bottiglieri T., et al. Treatment of AIDS-associated myelopathy with L-methionine. Neurology 2004, 63:1270-1275.
26. Diesing T., Swindells S., Gelbard H., et al. HIV-1 associated dementia: a basic science and clinical perspective. AIDS Read. 2002, 12:358-368.
27. Evans S., Ellis R., Chen H., et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011, 25:919-928.
28. Falusi O., French A., Seaberg E., et al. Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin. Infect. Dis. 2002, 35:1414-1417.
29. Feldmesser M., Harris C., Reichberg S., et al. Serum cryptococcal antigen in patients with AIDS. Clin. Infect. Dis. 1996, 23:827-830.
30. Fine H., Mayer R. Primary central system lymphoma. Ann Intern Med 1993, 119:1093-1104.
31. Fischer L., Korfel A., Kiewe P., et al. Systemic high dose methotrexate plus ifosfamide is highly effective for central nervous system involvement of lymphoma. Ann. Hematol. 2009, 88:133-139.
32. French M., Lenzo N., John M., et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000, 1:107-115.
33. Gans J., Tiessens G., Portegies P., et al. Predominance of polymorphonuclear leucocytes in cerebrospinal fluid of AIDS patients with cytomegalovirus polyradiculomyelitis. J. AIDS 1990, 3:1155-1158.
34. Gartner S., Liu Y. Insights into the role of immune activation in HIV neuropathogenesis. J. Neurovirol. 2002, 8:69-75.
35. Garvey L., Pavese N., Politis M., et al. Microglial cell activation is visualized with [11C]-PK11195 positron emission tomography in neurologically asymptomatic HIV-infected subjects on suppressive ART 2012.
36. Geraci A.P., Di Rocco A. Anti-HIV therapy. AIDS 2000, 14:2059-2061.
37. Ghanem K., Moore R., Rompalo A., et al. Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin. Infect. Dis. 2009, 48:816-821.
38. Graybill J., Sobel J., Saag M., et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin. Infect. Dis. 2000, 30:47-54.
39. Haase A. Pathogenesis of lentivirus infections. Nature 1986, 322:130-136.
40. Hahn K., Arendt G., Braun J., et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J. Neurol. 2004, 251:1260-1266.
41. Hamill R., Sobel J., El-Sadr W., et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin. Infect. Dis. 2010, 51:225-232.
42. Jabs D., Van Natta M., Holbrook J., et al. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology 2007, 114:780-786.
43. Johnson B., Fram E., Johnson P., et al. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am. J. Neuroradiol. 1997, 18:563-572.
44. Kaplan J., Handson D., Dworkin M.S., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2000, 30(Suppl 1):S5-S14.
45. Kaplan J., Benson C., Holmes K., et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep. 2009, 58:1-207.
46. Katrak S., Shembalkar P., Bijwe S., et al. The clinical, radiological and pathological profile of tuberculous meningitis in patients with and without human immunodeficiency virus infection. J. Neurol. Sci. 2000, 181:118-126.
47. Kingston A., Vujevich J., Shapiro M., et al. Seronegative secondary syphilis in 2 patients coinfected with human immunodeficiency virus. Arch. Dermatol. 2005, 141:431-433.
48. Kiprov D., Pfaeffl W., Parry G., et al. Antibody-mediated peripheral neuropathies associated with ARC and AIDS: successful treatment with plasmapheresis. J. Clin. Apher. 1988, 4:3-7.
49. Koralnik I., Wüthrich C., Dang X., et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann. Neurol. 2005, 57:576-580.
50. Lawn S., Bekker L., Miller R. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect. Dis. 2005, 5:361-373.
51. Leger J., Bouche P., Bolgert F., et al. The spectrum of polyneuropathies in patients infected with HIV. J. Neurol. Neurosurg. Psychiatry 1989, 52:1369-1374.
52. Letendre S., Ellis R., Ances B., et al. Neurologic complications of HIV disease and their treatment. Top. HIV Med. 2010, 18:45-55.
53. Li W., Galey D., Mattson M., et al. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. AIDS 2005, 19:1367.
54. Luft B., Remington J. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992, 15:211-222.
55. Luft B., Hafner R., Korzun A., et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N. Engl. J. Med. 1993, 329:995-1000.
56. MacMahon E., Glass J., Hayward S., et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991, 338:969-973.
57. MacNealy M., Newton H., McGregor J., et al. Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy. J. Neurooncol 2008, 90:329-333.
58. Malamut R., Leopold N., Chester P., et al. The treatment of HIV-associated chronic inflammatory demyelinating polyneuropathy (HIV-CIDP) with intravenous immunoglobulin (IVIG). Neurology 1992, 42:335.
59. Marra C., Maxwell C., Smith S., et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J. Infect. Dis. 2004, 189:369-376.
60. Maschke M., Kastrup O., Esser S., et al. Incidence and prevalence of neurological disorders with HIV. J. Neurol. Neurosurg. Psychiatry 2000, 69:376-380.
61. Miro J., Murray H. Toxoplasmosis. AIDS Therapy 2008, 659-681. Churchill Livingstone, Philadelphia. 3rd edn. R. Dolin, H. Masur, M. Saag (Eds.).
62. Mirza S., Phelan M., Rimland D. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin. Infect. Dis. 2003, 36:789-794.
63. Montoya J., Liesenfeld O. Toxoplasmosis. Lancet 2004, 363:1965-1976.
64. Murakawa G., Kerschmann R., Berger T. Cutaneous Cryptococcus infection and AIDS. Report of 12 cases and review of the literature. Arch. Dermatol. 1996, 132:545-548.
65. Nelson D., Martz K., Bonner H., et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 1992, 23:9-17.
66. Nogui F., Mattas S., Junior G., et al. Neurotoxoplasmosis diagnosis for HIV-1 patients by real-time PCR of cerebrospinal fluid. Braz. J. Infect. Dis. 2009, 13:18.
67. Offenbacher H., Fazekas F., Schmidt R., et al. MRI in tuberculous meningoencephalitis: report of four cases and review of the neuroimaging literature. J. Neurol. 1991, 238:340.
68. Pai M., Flores L., Pai N., et al. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect. Dis. 2003, 3:633-643.
69. Palella F., Kathleen M., Moorman A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 1998, 338:853-860.
70. Park B., Wannemuehler K., Marston B., et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
71. Perfect J., Dismukes W., Dromer F., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin. Infect. Dis. 2010, 50:291-322.
72. Petito C., Navia B., Cho E., et al. Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 1985, 312:874-879.
73. Petratos S., Turnbull V., Papadopoulos R., et al. Antibodies against peripheral myelin glycolipids in people with HIV infection. Immunol. Cell Biol. 1998, 76:535-541.
74. Piette A., Tusseau F., Vignon D., et al. Acute neuropathy coincident with seroconversion for anti-LAV/HTLV-III. Lancet 1986, 1:852.
75. Piliero P., Estanislao L., Simpson D. Diaphragmatic paralysis due to isolated phrenic neuropathy in an HIV-infected man. Neurology 2004, 62:154-155.
76. Porter S., Sande M. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N. Engl. J. Med. 1992, 327:1643-1648.
77. Rock R., Gekker G., Hu S., et al. Role of microglia in central nervous system infections. Clin. Microbiol. Rev. 2004, 17:942-964.
78. Rock R., Olin M., Baker C., et al. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin. Microbiol. Rev. 2008, 21:243-261.
79. Rolfs R., Joesoef R., Hendershot E., et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N. Engl. J. Med. 1997, 337:307-314.
80. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J. Neurovirol. 2002, 8(Suppl 2):115-121.
81. Sacktor N., Wong M., Nakasujja N., et al. The international HIV dementia scale: a new rapid screening test for HIV dementia. AIDS 2005, 19:1367-1374.
82. Shelburne S., Darcourt J., White C., et al. The role of immune reconstitution inflammatory syndrome in AIDS related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2005, 40:1049-1052.
83. Sidtis J., Gatsonis C., Price R., et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann. Neurol. 1993, 33:343-349.
84. Simona B., Giliola C., Francesca M., et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin. Infect. Dis. 2005, 40:738-744.
85. Simpson D., Olney R., McArthur J., et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000, 54:2115-2119.
86. Simpson D., Brown S., Tobias J., et al. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008, 70:2305-2313.
87. Simpson D., Schifitto G., Clifford D., et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 2010, 74:413-420.
88. Skiest D. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin. Infect. Dis. 2002, 34:103-115.
89. Skiest D., Erdman W., Chang W., et al. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J. Infect. 2000, 40:274-281.
90. Skiest D., Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central system lymphoma. AIDS 2003, 17:1787-1793.
91. Skopelitis E., Kokotis P., Kontos A., et al. Distal sensory polyneuropathy in HIV-positive patients in the HAART era: an entity underestimated by clinical examination. Int. J. STD AIDS 2006, 17:467-472.
92. Smith D., Guillemin G., Pemberton L., et al. Quinolinic acid is produced by macrophages stimulated by platelet activation factor, Nef, and Tat. J. Neurovirol. 2001, 7:56-60.
93. Stern Y., McDermott M., Albert S., et al. Factors associated with incident human immunodeficiency virus-dementia. Arch. Neurol. 2001, 58:473-479.
94. Sullivan F., Swan I., Donnan P., et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N. Engl. J. Med. 2007, 357:1598-1607.
95. Surawicz T., McCarthy B., Kupelian V., et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro-oncol. 1999, 1:14-25.
96. Thwaites G., Nguyen D., Nguyen H., et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 2004, 351:1741-1751.
97. Thwaites G., Duc Bang N., Huy Dung N., et al. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J. Infect. Dis. 2005, 192:2134-2141.
98. Venkataramana A., Pardo C., McArthur J., et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006, 67:383-388.
99. Verma S., Micsa E., Estanislao L., et al. Neuromuscular complications in HIV. Curr. Neurol. Neurosci. Rep. 2004, 4:62-67.
100. Wallace M., Rossetti R., Olson P. Cats and toxoplasmosis risk in HIV-infected adults. JAMA 1993, 269:76-77.
101. Wechsler A., HoD D.D. BilateralBell's palsy at the time of HIV seroconversion. Neurology 1989, 39:747-748.
102. Vibhagool A., Sungkanuparph S., Mootsikapun P., et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin. Infect. Dis. 2003, 36:1329-1331.
103. Workowski K., Berman S. Sexually transmitted diseases treatment guidelines. MMWR Recomm. Rep. 2010, 59:33-34.